Found: 29
Select item for more details and to access through your institution.
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 993, doi. 10.1007/s13555-024-01145-9
- By:
- Publication type:
- Article
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 2, p. 299, doi. 10.1007/s40257-024-00846-3
- By:
- Publication type:
- Article
Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open‐Label, Phase 1 Study.
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 1, p. 67, doi. 10.1002/jcph.2347
- By:
- Publication type:
- Article
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial.
- Published in:
- Pediatric Dermatology, 2023, v. 40, n. 6, p. 1003, doi. 10.1111/pde.15378
- By:
- Publication type:
- Article
Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database.
- Published in:
- Journal of Dermatology, 2023, v. 50, n. 9, p. 1121, doi. 10.1111/1346-8138.16839
- By:
- Publication type:
- Article
Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 8, p. 1733, doi. 10.1007/s13555-023-00937-9
- By:
- Publication type:
- Article
Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 3, p. 867, doi. 10.1007/s13555-021-00512-0
- By:
- Publication type:
- Article
Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 11, doi. 10.1002/cpdd.741
- By:
- Publication type:
- Article
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
- Published in:
- Modern Rheumatology, 2019, v. 29, n. 5, p. 756, doi. 10.1080/14397595.2018.1553489
- By:
- Publication type:
- Article
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
- Published in:
- Arthritis & Rheumatology, 2017, v. 69, n. 4, p. 728, doi. 10.1002/art.39996
- By:
- Publication type:
- Article
Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
- Published in:
- International Journal of Rheumatic Diseases, 2016, v. 19, n. 12, p. 1216, doi. 10.1111/1756-185X.12901
- By:
- Publication type:
- Article
Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
- Published in:
- Arthritis Research & Therapy, 2016, v. 18, p. 1, doi. 10.1186/s13075-016-1049-3
- By:
- Publication type:
- Article
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
- Published in:
- Rheumatology, 2016, v. 55, n. 6, p. 1031, doi. 10.1093/rheumatology/kev442
- By:
- Publication type:
- Article
Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis.
- Published in:
- Modern Rheumatology, 2016, v. 26, n. 2, p. 318, doi. 10.3109/14397595.2015.1012799
- By:
- Publication type:
- Article
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
- Published in:
- Arthritis Research & Therapy, 2015, v. 17, p. 1, doi. 10.1186/s13075-015-0825-9
- By:
- Publication type:
- Article
Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial.
- Published in:
- Arthritis Care & Research, 2015, v. 67, n. 4, p. 475, doi. 10.1002/acr.22453
- By:
- Publication type:
- Article
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis.
- Published in:
- Annals of Internal Medicine, 2013, v. 159, n. 4, p. 253, doi. 10.7326/0003-4819-159-4-201308200-00006
- By:
- Publication type:
- Article
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors.
- Published in:
- Arthritis Research & Therapy, 2011, v. 13, n. 1, p. 1, doi. 10.1186/ar3249
- By:
- Publication type:
- Article
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 69, n. 2, p. 143, doi. 10.1111/j.1365-2125.2009.03570.x
- By:
- Publication type:
- Article
Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis.
- Published in:
- 2009
- By:
- Publication type:
- Letter
Where Is the Evidence That the Resurgence of Nomograms Is Harmful?
- Published in:
- 2009
- By:
- Publication type:
- Letter
Therapeutic targeting of Janus kinases.
- Published in:
- Immunological Reviews, 2008, v. 223, n. 1, p. 132, doi. 10.1111/j.1600-065X.2008.00644.x
- By:
- Publication type:
- Article
V Alpha Gene Usage in Rheumatoid Compared with Osteoarthritic Synovial Tissue T Cells.
- Published in:
- DNA & Cell Biology, 1994, v. 13, n. 9, p. 923, doi. 10.1089/dna.1994.13.923
- By:
- Publication type:
- Article